Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;28(7):355-63.
doi: 10.1093/intimm/dxw018. Epub 2016 Mar 28.

Chimeric antigen receptor-modified T cells strike back

Affiliations
Review

Chimeric antigen receptor-modified T cells strike back

Matthew J Frigault et al. Int Immunol. 2016 Jul.

Abstract

Chimeric antigen receptors (CARs) are engineered molecules designed to endow a polyclonal T-cell population with the ability to recognize tumor-associated surface antigens. In their simplest form, CARs comprise a targeting moiety in the form of a single-chain variable fragment from an antibody connected to various intracellular signaling domains allowing for T-cell activation. This powerful approach combines the specificity of an antibody with the cytotoxic ability of a T cell. There has been much excitement since early phase trials of CAR-T cells targeting CD19 expressed on B-cell malignancies demonstrated remarkable efficacy in inducing long-term, stable remissions in otherwise relapsed/refractory disease. Despite these successes, we have just begun to understand the intricacies of CAR biology with efforts underway to utilize this platform in the treatment of other, previously refractory malignancies. Challenges currently include identification of viable cancer targets, management strategies for potentially severe and irreversible toxicities and overcoming the immunosuppressive nature of the tumor microenvironment. This review will focus on basic CAR structure and function, previous success and new approaches aimed at the broader application of CAR-T-cell therapy.

Keywords: T-cell therapy; cellular immunotherapy; chimeric antigen receptor; clinical immunology; gene therapy.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
The evolution of CARs. Early CARs were molecules composed of ectodomains from immunoglobulin VH or VL or from various receptors, fused with the TCR α or β chain. Modern CARs are composed of an extracellular antigen-binding domain usually derived from an immunoglobulin scFv, an extracellular spacer or ‘hinge’, a transmembrane domain and various ICDs required for T-cell activation.
Fig. 2.
Fig. 2.
Overview of CAR adoptive cell transfer. T cells are collected via apheresis, expanded ex vivo and genetically modified to express a desired CAR construct before they are infused back into the patient. Reproduced with permission of Annual Review of Medicine, Volume 65 Copyright © 2014 by Annual Reviews, http://www.annualreviews.org.

References

    1. Burnet F. M. 1967. Immunological aspects of malignant disease. Lancet 1:1171. - PubMed
    1. Gross G. Waks T. and Eshhar Z. 1989. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86:10024. - PMC - PubMed
    1. Irving B. A. and Weiss A. 1991. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64:891. - PubMed
    1. Letourneur F. and Klausner R. D. 1991. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc. Natl Acad. Sci. USA 88:8905. - PMC - PubMed
    1. Romeo C. and Seed B. 1991. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64:1037. - PubMed

Publication types

Substances

LinkOut - more resources